Dec 17, 2025

Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics:

• Introduction: Tail on the Curve? (0:00)
• First-Line Chemoimmunotherapy (10:45)
• Maintenance Lurbinectedin (28:42)
• Second-Line Treatment, Tarlatamab (45:35)
• Ongoing Research (53:20)

CME information and select...

Dec 12, 2025

Featuring perspectives from Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields, moderated by Dr Stephen “Fred” Divers, including the following topics: 

• Introduction (0:00)
• Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) — Dr Gainor, MD (5:32)
• Case: A woman in her mid 60s with ALK-mutant...

Dec 10, 2025

Featuring an interview with Dr John V Heymach, including the following topics:

• Differentiating factors among various HER2 alterations in non-small cell lung cancer (NSCLC) (0:00)
• Activity of targeted agents across HER2 alterations in NSCLC (4:06)
• Available data with zongertinib and sevabertinib for HER2-mutant NSCLC...

Dec 9, 2025

Featuring a slide presentation and related discussion from Dr John V Heymach, including the following topics:

• Overview of the biology and treatment landscape of HER2-mutant non-small cell lung cancer (NSCLC) (0:00)
• Datasets evaluating trastuzumab deruxtecan for HER2-mutant NSCLC (5:03)
• Clinical data with zongertinib...

Nov 7, 2025

Featuring an interview with Dr Aaron Lisberg, including the following topics:

• Prevention and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (Dato-DXd) (0:00)
  • Rugo H et al. US expert Delphi consensus on the prevention and management of stomatitis in patients...